OmniAb, Inc.  announces the presentation of new scientific data on its OmnidAb^™ platform, the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society. The Company presented an overview of OmnidAb and its functionality to industry leaders and prospective customers today in a presentation by Christine Vuong, Ph.D., Senior Scientist, titled “Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding.”

“Our recent launch of OmnidAb is the latest example of OmniAb’s commitment to innovation and the intelligent expansion of our technology. OmnidAb is the first and only transgenic chicken that produces single-domain antibodies, which represent an important class due to their unique physical properties that can be leveraged for a variety of important applications,” said Matt Foehr, Chief Executive Officer of OmniAb. “Several current partners are already leveraging OmnidAb in active programs while many others have expressed interest in this platform given its versatility in important applications, including alternate routes of administration, diagnostic applications and therapeutic approaches beyond what is typically possible with conventional antibodies.”

The OmnidAb transgenic chicken novel host system builds upon the success of the Company’s OmniChicken^® legacy by expressing an optimized single-domain human framework that can generate modular building blocks well suited to support a variety of therapeutic modalities. OmnidAb antibodies target distinct epitopes and have favorable developability profiles with high expression levels in mammalian cells. Compared with traditional antibodies, sdAbs produced by OmnidAb chickens have a compact format that opens new opportunities and broad clinical applications.

“We believe the OmnidAb platform offers significant benefits due to its built-in use of an optimized human scaffold combined with efficient in vivo affinity maturation. This minimizes the need for downstream engineering and provides a functionally diverse immune repertoire that is unavailable from mammalian systems. There is growing industry interest in this modality, and we look forward to working with partners to advance their programs leveraging our new OmnidAb technology,” added Bill Harriman, Ph.D., Senior Vice President, Antibody Discovery of OmniAb.

OmniAb is showcasing OmnidAb and its entire technology stack at the 2023 Antibody Engineering & Therapeutics Conference at booth #300 at the Marriott Marquis San Diego Marina.

In addition, the Company will be highlighting its OmniDeep^™ suite of in silico tools at the Conference in a presentation titled “Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep” on Friday, December 15^th at 12:05 p.m. Pacific time. OmniDeep integrates the Company’s Biological Intelligence^™ with AI and uses in silico tools to better mine diverse immune repertoires. Bob Chen, Senior Director, Discovery Systems, will present a case study showcasing OmniDeep’s ability to empower large-scale antibody discovery while selecting high-affinity clones. OmniAb is leveraging its technology stack to offer partners new discovery workflows and optimization tools for existing discovery campaigns.